Momentum is building for the early December staging in Mumbai of the third CPhI India and second P-MEC India pharma ingredients, services and technologies event. A combined total of over 600 exhibitors from over 80 countries are expected at the Bombay Exhibition Centre for the 2009 events, being held on 1 – 3 December.
In addition to high quality exhibitors, the 2009 events include two new launches. BioPh India will focus on the convergence of technologies and business models in pharma and healthcare biotechnology – especially across the common interest areas of innovation, product development, clinical trials, manufacturing and supply logistics.
2009 also brings the debut of ICSE India, with emphasis on the very fast-growing outsourcing and contract services sector. The co-located additions of BioPh India and ICSE India to CPhI India and P-MEC India add impressive further depth and networking value to the combined events. The 2009 events will also be complemented by two major conferences.
CPhI India became the fourth member of the brand's global event "family" in 2006 and was joined by P-MEC India in 2007. The combined exhibitions are the largest pharma services event in India and South Asia. Despite the recent global slowdown, Indian pharma has maintained standout growth rates, with a sector forecast to quadruple, from US $6.3bn. in 2005 to US $25bn. in 2015.
In their mid-2009 report, and underlining the important addition of ICSE India – E&Y/OPPI (Ernst & Young/Organisation of Pharmaceutical Producers of India – OPPI) noted that India's outsourcing sector is growing at 43%, with drug discovery and development segment growing at 65% – well over three times the global average. India is targeting to become one of the top five innovator countries by 2020.
Growth will figure strongly in the major conferences complementing the exhibitions. These begin with the Indian Pharma Summit on Monday 30 November, focusing on: "The future of India Pharma – India Pharma Vision 2020" addressing the issues, opportunities and challenges for India as an emerging global pharma hub.
The event will be chaired by Ashok Kumar, Secty. Dept. of Pharmaceuticals and co-chaired by Glenn Saldhana, Chairman, FICCI National Pharmaceuticals Committee & MD and CEO, Glenmark Pharmaceuticals. Organisers are the Government of India's new Department of Pharmaceuticals and UBM India Pvt. Ltd. Venue is the Mumbai Grand Hyatt.
Staged alongside the first two days of CPhI India, in the BioPh pavilion at the Bombay Exhibition Centre, Biosimilars India 2009 will cover a wide range of topics in 17 sessions across three half-day modules.
"India is now moving towards centrestage in world pharma, with its overall pharma market growing at better than 9% – and key segments much faster. CPhI and the co-located events are the natural meeting point that enables a high level of networking and business development across the academic, development, R&D, services and manufacturing communities", said CPhI India Event Director Annemieke Timmers.
"With the BioPh India and ICSE India launches and a strong conference programme adding to a high level of pre-registrations, all our indications are that this year in Mumbai will see our strongest Indian events so far", added ICSE, BioPh and P-MEC Event Director Haf Cennydd.
Key industry organisations supporting the exhibitions will include Pharmexcil – the Government of India's pharmaceutical export promotion council; the Indian Drug Manufacturers Association (IDMA); the Organisation of Pharmaceutical Producers of India (OPPI) and the Bulk Drug Manufacturers Association (India) (BDMA).
The events are jointly organised by UBM International Media and sister company UBM India Pvt. Ltd.
UBM International Media's annual sister events for the pharma ingredients and services sector include Worldwide (Europe – October); Japan (April); China (June); and South America (August).